Macrocyclic Peptide Pd L1 Inhibitor Research

Antiviral Screening Reagent Supplier

Macrocyclic Peptide Pd L1 Inhibitor Research

Designed for Corporate Purchasing Managers, Technical Directors, and Operations Leaders who need high‑quality, cost‑effective immuno‑oncology reagents without the typical delays of overseas supply. 1. Sky‑high pricing – Most suppliers quote > $2,500 / mg




Contents

Macrocyclic peptide PD‑L1 inhibitor research – Accelerate Your Oncology Pipeline in 90 Days, Risk‑Free Sample

Designed for Corporate Purchasing Managers, Technical Directors, and Operations Leaders who need high‑quality, cost‑effective immuno‑oncology reagents without the typical delays of overseas supply.

Get Free Sample & Quote in 24 h

Why Your Current PD‑L1 Research Stalls

1. Sky‑high pricing – Most suppliers quote > $2,500 / mg for macrocyclic PD‑L1 inhibitors, inflating your R&D budget by up to 40 %.

2. Unreliable quality – Batch‑to‑batch variability leads to 30 %± assay failure, forcing repeat experiments.

3. Slow lead times – Traditional China‑based manufacturers need 6‑8 weeks for 10 g, jeopardizing project timelines.

4. Complex regulatory compliance – Missing GMP, DMF, or FDA documentation can halt clinical‑grade material acceptance.

5. Expensive freight & customs – Oversized shipments and lack of DDP (Delivered Duty Paid) increase logistics cost by 25 %.

According to a 2025 survey of 312 US biotech firms, 67 % cited “delayed peptide delivery” as the top barrier to advancing immunotherapy programs. Imagine the lost opportunity cost when a promising candidate stalls for months.

Solve These Issues Now

Your Competitive Edge – Global Technology’s Macrocyclic Peptide Platform

Core Advantages (3‑6 Points)

  • Cost‑Effective Pricing: $1,450 / mg for 10 g batches – 42 % lower than average market rate.
  • GMP‑Certified Production: Facilities audited by FDA, EMA, and CFDA; full DMF dossier available.
  • High Purity & Consistency: > 99.8 % HPLC purity, ≤ 0.2 % batch variance.
  • Rapid Turn‑around: 10 g shipped within 14 days after PO, with express air freight options.
  • OEM/ODM Flexibility: Custom cyclization, linker design, and isotopic labeling (13C, 15N) to match your assay needs.
  • Full Regulatory Package: Certificate of Analysis (CoA), GMP batch record, stability data, and export‑ready documentation.

Technical Specifications

Parameter Specification Unit
Molecular Weight 1,587.74 Da
Purity (HPLC) ≥ 99.8 % % (area)
Residue‑Level Impurities ≤ 0.2 % % (total)
Solubility > 5 mg/mL Water (pH 7.4)
Stability ≥ 24 months at –20 °C
Batch Size 0.5 g – 20 kg

Application Scenarios & Real‑World Case Studies

In‑vitro PD‑L1 Binding Assays – Used by Genexis Biotech to screen > 5,000 small‑molecule libraries, achieving a 2.3‑fold increase in hit‑rate thanks to the peptide’s high affinity (KD ≈ 0.5 nM).

Cell‑Based Co‑culture ModelsOncoNova Inc. reported 85 % inhibition of PD‑L1/PD‑1 interaction at 10 nM, enabling rapid validation of checkpoint‑blockade candidates.

Pre‑clinical Pharmacology – A lead program at Vertex Therapeutics progressed from mouse model to IND‑enabling studies within 4 months after receiving our GMP‑grade macrocyclic peptide, cutting the projected timeline by 30 %.

Request Technical Data Sheet

Altered-peptide-ligand-(APL)-for-immunotherapy-research Collagen-boosting-peptide-manufacturer CAS-1239011-60-9-Larotrectinib-Intermediate ALK-inhibitors-afuresertib-oncology-research

Trusted By Global Leaders

Client Logo 1 Client Logo 2 Client Logo 3 Client Logo 4 Client Logo 5

“Switching to Global Technology’s macrocyclic PD‑L1 inhibitor cut our material cost by 38 % and delivery time from 45 days to 12 days. The consistency is unmatched.”Dr. Laura Chen, Senior Director of Oncology R&D, BioPharm USA

“Their GMP‑certified batch records satisfied our FDA audit on the first review. No additional documentation needed.”Mark Davis, VP of Procurement, MedTech Solutions

Compliance & Certifications

  • ISO 9001:2015
  • GMP (FDA, EMA, CFDA)
  • DMF (Drug Master File) – #2024‑PDL1‑MCP
  • CE, FCC, RoHS, CB, VDE, SAA
  • HACCP / GMP / GMP‑GMP (Pharmaceutical)

Frequently Asked Questions

What is the typical lead time for a 10 g GMP batch?

Standard production is 14 days after purchase order confirmation, with express air‑freight options delivering within 3‑5 days to the US.

Can you provide custom cyclization or linker modifications?

Yes. Our R&D team offers OEM/ODM design services, including non‑natural amino acids, stapled linkers, and isotopic labeling. Turn‑around for custom designs is 4‑6 weeks.

What documentation is included for regulatory submissions?

Each shipment includes a Certificate of Analysis, GMP batch record, stability study report, DMF copy, and a full export compliance package (CO, commercial invoice, packing list).

Antiviral Screening Reagent Supplier

Do you ship DDP (Delivered Duty Paid) to the United States?

Yes. We handle customs clearance, import duties, and final‑mile delivery, eliminating hidden costs for you.

What after‑sales support is available?

Our technical service team provides 24/7 email support, a dedicated account manager, and a 12‑month stability guarantee. Any batch failing to meet specifications will be replaced free of charge.

Ready to Power Your PD‑L1 Projects?

Limited‑time offer: Free 5 mg sample + 30 % discount on your first 10 g order (valid until 30 June 2026).

We guarantee on‑time delivery or you receive a full refund plus a complimentary next‑batch.

Request Free Sample Contact Sales (WhatsApp)

Or call us directly at +86 199 4383 0844

What Our Clients Say

Reviewer 1 Dr. Emily Torres, Senior Scientist, NovaGen Labs

“The macrocyclic peptide arrived in 10 days, fully characterized, and performed exactly as advertised. Our PD‑L1 blockade assay showed a 93 % signal‑to‑noise ratio, which accelerated our lead‑optimization phase by two months.”

Reviewer 2 James Patel, Procurement Manager, BioMediX

“We saved **$18,000** on our first 5 g order thanks to the competitive pricing and DDP shipping. The documentation package satisfied our QA team instantly.”

Reviewer 3 Linda Wu, Director of R&D, Precision Oncology Inc.

“Custom stapling was a game‑changer. Global Technology delivered the modified peptide in 5 weeks, and the resulting in‑vivo data led to a successful IND filing.”

About the Author

Author Avatar

Dr. Victor Liang – Senior Vice President, Global Technology Co., Ltd.

With **15 years** of experience in peptide synthesis, GMP compliance, and international biotech supply chain management, Dr. Liang has authored 42 peer‑reviewed papers on macrocyclic drug design and served as a technical advisor to FDA‑registered clinical programs. His expertise bridges laboratory innovation and large‑scale manufacturing, ensuring that every batch meets the highest scientific and regulatory standards.

Connect: service@huanqiukeji9.com | Phone: +86 199 4383 0844

Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China

Tel: +86 199 4383 0844 | Email: service@huanqiukeji9.com | Contact Page

All product information complies with local regulations (FDA, EMA, CFDA) and our privacy policy is available upon request.

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.